Novartis` Cosentyx gets US nod for hidradenitis suppurativa
Novartis` Biologic Cosentyx (secukinumab) Receives Approval in the U.S.
EAST HANOVER, N.J., Oct. 6, 2023 /PRNewswire/ -- Novartis, a global leader in immuno-dermatology and rheumatology, announced today that the US Food and Drug Administration (FDA) has approved an intravenous (IV) formulation of Cosentyx® (secukinumab) for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Cosentyx is the only treatment approved in an IV formulation that specifically targets and blocks interleukin-17A (IL-17A), and the only non-tumor necrosis factor alpha (TNF-?) IV option available in all these indications. The IV formulation of Cosentyx offers patients a monthly 30-minute, weight-based dosing option, requiring no pre-medication and no lab monitoring.1 The new IV administration option will be available in Q4 of 2023.
Novartis`s Cosentyx (secukinumab) Receives Approval in Europe
Basel, June 1, 2023 — Novartis announced today that the European Commission (EC) has approved Cosentyx® (secukinumab) for use in adults with active moderate to severe hidradenitis suppurativa (HS) and an inadequate response to conventional systemic HS therapy7.
Novartis' Biologic Cosentyx (Secukinumab) Receives Approval in the U.S.
Novartis’ star drug Cosentyx recently hit a sales slump thanks to tough competition from newer biologics. But for the company’s next phase of growth in immunology, the Swiss pharma giant is targeting a slew of indications that remain underserved.
Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion and recommended granting a marketing authorization for Cosentyx® (secukinumab) in adults with active moderate to severe hidradenitis suppurativa (HS).
Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®
Shares in French biotech Inventiva were on the slide this morning after AbbVie revealed that it had decided to abandon development of cedirogant, their drug candidate for autoimmune diseases including psoriasis.